Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 10.5 CAD 2.44% Market Closed
Market Cap: 120.4m CAD

Biosyent Inc
Investor Relations

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

Show more
Loading
RX
S&P TSX Composite Index (Canada)

Earnings Calls

2024 Q4
Feb 26, 2025
Show Transcript
Previous
Next
Adecco Delivers Resilience Amid Market Challenges
2024 Q4
Feb 26, 2025

In Q4 2024, Adecco faced a challenging market, posting revenues of EUR 5.9 billion, down 4.6% year-on-year. However, it demonstrated resilience with a gross margin of 19.2% and effective cost management, achieving EUR 491 million in operating cash flow. The company’s EBITA margin was reported at 3.2%. Adecco aims for a net debt-to-EBITDA ratio below 1.5x by 2027, supported by a new dividend policy proposing CHF 1 per share, reflecting 42% of earnings. Looking ahead, management anticipates stable volumes and aims for 1-2% revenue growth in H1 2025, indicating a cautious optimism for recovery.

Show Full Analysis

Management

Mr. René C. Goehrum
Chairman, CEO & President
No Bio Available
Mr. Robert J. March
VP of Finance & CFO
No Bio Available
Mr. Joost van der Mark
Vice President of Corporate Development
No Bio Available
Ms. Neelu Atwal
Director of Human Resources
No Bio Available

Contacts

Address
ONTARIO
Mississauga
2476 Argentia Road, Suite 402
Contacts
+19052060013.0
www.biosyent.com